Showing 85 to 96 of 151 results
EU Proposes "Buy European" Mechanism to Tackle Critical Medicine Shortages
The EU proposed a new critical medicines act to address drug shortages, including a "Buy European" mechanism prioritizing supply security over price in public procurement, and a coordinated supply system for medicines of common interest, impacting supply chain resilience and access to essential drug...
EU Proposes "Buy European" Mechanism to Tackle Critical Medicine Shortages
The EU proposed a new critical medicines act to address drug shortages, including a "Buy European" mechanism prioritizing supply security over price in public procurement, and a coordinated supply system for medicines of common interest, impacting supply chain resilience and access to essential drug...
Progress
40% Bias Score
BMY Stock: Strong Q4 Results Contrast with Long-Term Underperformance
Bristol Myers Squibb's stock (BMY) is up 7% year-to-date, outperforming the S&P 500, but down 9% since early 2023 due to a lower P/S ratio despite increased revenue ($48.3B) and share buybacks, driven by declining legacy drug sales and upcoming biosimilar competition for Eliquis, offset by new drugs...
BMY Stock: Strong Q4 Results Contrast with Long-Term Underperformance
Bristol Myers Squibb's stock (BMY) is up 7% year-to-date, outperforming the S&P 500, but down 9% since early 2023 due to a lower P/S ratio despite increased revenue ($48.3B) and share buybacks, driven by declining legacy drug sales and upcoming biosimilar competition for Eliquis, offset by new drugs...
Progress
40% Bias Score
AI Accelerates Pharmaceutical Drug Development
AI is transforming the pharmaceutical industry by accelerating drug discovery, optimizing clinical trials, and enabling precision medicine, leading to faster, cheaper, and more effective treatments.
AI Accelerates Pharmaceutical Drug Development
AI is transforming the pharmaceutical industry by accelerating drug discovery, optimizing clinical trials, and enabling precision medicine, leading to faster, cheaper, and more effective treatments.
Progress
44% Bias Score
Trump Announces Steep Tariffs on Autos, Semiconductors, and Pharmaceuticals
President Trump announced 25% tariffs on auto imports, semiconductors, and pharmaceuticals, starting April 2, aiming to boost domestic production and address perceived unfair trade practices, potentially impacting consumers and businesses significantly.
Trump Announces Steep Tariffs on Autos, Semiconductors, and Pharmaceuticals
President Trump announced 25% tariffs on auto imports, semiconductors, and pharmaceuticals, starting April 2, aiming to boost domestic production and address perceived unfair trade practices, potentially impacting consumers and businesses significantly.
Progress
52% Bias Score
Record Irish Exports Amidst Trump's Planned Tariffs
Ireland's 2024 exports hit a record €223.8 billion, a 14% rise fueled by a 29% jump in medical and pharmaceutical exports (€99.9 billion) amidst President Trump's planned global tariffs and a record US trade deficit.
Record Irish Exports Amidst Trump's Planned Tariffs
Ireland's 2024 exports hit a record €223.8 billion, a 14% rise fueled by a 29% jump in medical and pharmaceutical exports (€99.9 billion) amidst President Trump's planned global tariffs and a record US trade deficit.
Progress
48% Bias Score
Premarket Stock Volatility: Mixed Earnings Reports Drive Market Fluctuations
Premarket trading saw significant stock fluctuations; Ford dropped over 5% due to soft 2025 guidance, Bristol Myers Squibb fell nearly 6% from missing revenue estimates, and Qualcomm declined 5% despite exceeding expectations, while Skyworks Solutions plummeted almost 30% following a CEO change.
Premarket Stock Volatility: Mixed Earnings Reports Drive Market Fluctuations
Premarket trading saw significant stock fluctuations; Ford dropped over 5% due to soft 2025 guidance, Bristol Myers Squibb fell nearly 6% from missing revenue estimates, and Qualcomm declined 5% despite exceeding expectations, while Skyworks Solutions plummeted almost 30% following a CEO change.
Progress
36% Bias Score
Weight-Loss Drugs Linked to Tripled Depression Risk
A new study reveals that weight-loss drugs like Wegovy, Ozempic, and Saxenda nearly triple the risk of depression in obese patients, alongside other medications including PPIs and beta-blockers, raising concerns about their widespread use and potential mental health effects.
Weight-Loss Drugs Linked to Tripled Depression Risk
A new study reveals that weight-loss drugs like Wegovy, Ozempic, and Saxenda nearly triple the risk of depression in obese patients, alongside other medications including PPIs and beta-blockers, raising concerns about their widespread use and potential mental health effects.
Progress
52% Bias Score
US Tariffs on Pharmaceuticals: Expected Price Increases and Shortages
The Trump administration levied tariffs on China, Mexico, and Canada, ostensibly targeting fentanyl but impacting the U.S. pharmaceutical supply chain, causing predicted drug price increases of at least 10%, and potentially exacerbating existing drug shortages due to 80% of drug ingredients being so...
US Tariffs on Pharmaceuticals: Expected Price Increases and Shortages
The Trump administration levied tariffs on China, Mexico, and Canada, ostensibly targeting fentanyl but impacting the U.S. pharmaceutical supply chain, causing predicted drug price increases of at least 10%, and potentially exacerbating existing drug shortages due to 80% of drug ingredients being so...
Progress
56% Bias Score
Trump Announces 25% Tariffs on Cars, Chips, and Pharmaceuticals
President Trump announced plans to impose approximately 25% tariffs on imported cars, semiconductors, and pharmaceuticals by April 2, potentially impacting foreign automakers and raising consumer prices, as part of his protectionist trade strategy.
Trump Announces 25% Tariffs on Cars, Chips, and Pharmaceuticals
President Trump announced plans to impose approximately 25% tariffs on imported cars, semiconductors, and pharmaceuticals by April 2, potentially impacting foreign automakers and raising consumer prices, as part of his protectionist trade strategy.
Progress
56% Bias Score
Trump Announces Steep Tariffs on Autos, Semiconductors, and Pharmaceuticals
President Trump announced 25% tariffs on auto imports, semiconductors, and pharmaceuticals, starting April 2nd, aiming to balance trade and reshore industries, potentially impacting consumers and businesses with higher prices and affecting Asian and European companies.
Trump Announces Steep Tariffs on Autos, Semiconductors, and Pharmaceuticals
President Trump announced 25% tariffs on auto imports, semiconductors, and pharmaceuticals, starting April 2nd, aiming to balance trade and reshore industries, potentially impacting consumers and businesses with higher prices and affecting Asian and European companies.
Progress
52% Bias Score
Airline Stocks Soar on Lower Oil Prices, FTSE 100 Hits Record High
Driven by lower oil prices and positive broker ratings, airline stocks like EasyJet and Wizz Air soared, while IAG saw mixed results; the FTSE 100 hit a record high despite higher-than-expected US inflation, contrasting with the FTSE 250's decline.
Airline Stocks Soar on Lower Oil Prices, FTSE 100 Hits Record High
Driven by lower oil prices and positive broker ratings, airline stocks like EasyJet and Wizz Air soared, while IAG saw mixed results; the FTSE 100 hit a record high despite higher-than-expected US inflation, contrasting with the FTSE 250's decline.
Progress
36% Bias Score
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Progress
48% Bias Score
Showing 85 to 96 of 151 results